| Name | Title | Contact Details |
|---|
VISTA HealthPlan is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
Predictive Physiology and Medicine (PPM) is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oral Surgery Partners is a practice management company that provides professional management services for leading oral diagnostic and surgical practices for any issues that affect the mouth, teeth, and facial region.
Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team`s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies.